
    
      Estimated enrollment:

      Total of 24 subjects:

      mild to moderate psoriasis patients will be randomized into treatment group (n=16) placebo
      group (n=8)

      Study evaluation:

      A baseline and end of the study evaluation on the patients will be performed, including
      physical examination, hemogram and blood biochemical analysis (including glutamic-oxaloacetic
      transaminase, glutamic-pyruvic transaminase, and creatinine measurement). The baseline and
      end of the study of total body surface area involvement and Psoriasis Area Severity Index
      (PASI), PGA, OTPSS scores will be also calculated.
    
  